EA202191120A3 - PEPTIDES AND THEIR COMBINATIONS FOR USE IN CANCER IMMUNOTHERAPY - Google Patents

PEPTIDES AND THEIR COMBINATIONS FOR USE IN CANCER IMMUNOTHERAPY

Info

Publication number
EA202191120A3
EA202191120A3 EA202191120A EA202191120A EA202191120A3 EA 202191120 A3 EA202191120 A3 EA 202191120A3 EA 202191120 A EA202191120 A EA 202191120A EA 202191120 A EA202191120 A EA 202191120A EA 202191120 A3 EA202191120 A3 EA 202191120A3
Authority
EA
Eurasian Patent Office
Prior art keywords
peptides
present
tumor
cancer immunotherapy
relates
Prior art date
Application number
EA202191120A
Other languages
Russian (ru)
Other versions
EA202191120A2 (en
Inventor
Морено Ди Марко
Себастьян Хаен
Дэниэл Ковапевски
Маркус Пёффпер
Анника Непьде
Ганс-Георг Раммензее
Стефан Стеванович
Нико Траутвайн
Джулиана Сара Вапьц
Original Assignee
Имматикс Байотекнолоджиз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Имматикс Байотекнолоджиз Гмбх filed Critical Имматикс Байотекнолоджиз Гмбх
Publication of EA202191120A2 publication Critical patent/EA202191120A2/en
Publication of EA202191120A3 publication Critical patent/EA202191120A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)

Abstract

Настоящее изобретение относится к пептидам, белкам, нуклеиновым кислотам и клеткам для применения в иммунотерапевтических методах. В частности, настоящее изобретение относится к иммунотерапии рака. Настоящее изобретение относится далее к опухолеассоциированным пептидным эпитопам Т-клеток, в отдельности или в комбинации с другими опухолеассоциированными пептидами, которые могут, например, служить в качестве активных фармацевтических ингредиентов вакцинных композиций, стимулирующих противоопухолевые иммунные ответы, или стимулировать Т-клетки ex vivo с их перенесением в организм пациента. Пептиды, связанные с молекулами главного комплекса гистосовместимости (MHC), или пептиды в отдельности могут быть также мишенями антител, растворимых Т-клеточных рецепторов и других связывающих молекул.The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to cancer immunotherapy. The present invention further relates to tumor-associated T cell peptide epitopes, alone or in combination with other tumor-associated peptides, which can, for example, serve as active pharmaceutical ingredients in vaccine compositions that stimulate anti-tumor immune responses or stimulate T cells ex vivo with their transfer to the patient's body. Peptides associated with major histocompatibility complex (MHC) molecules, or peptides alone, may also be targets for antibodies, soluble T-cell receptors, and other binding molecules.

EA202191120A 2017-04-10 2018-04-10 PEPTIDES AND THEIR COMBINATIONS FOR USE IN CANCER IMMUNOTHERAPY EA202191120A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762483702P 2017-04-10 2017-04-10

Publications (2)

Publication Number Publication Date
EA202191120A2 EA202191120A2 (en) 2021-08-31
EA202191120A3 true EA202191120A3 (en) 2022-01-31

Family

ID=67439454

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201992417A EA201992417A1 (en) 2017-04-10 2018-04-10 PEPTIDES AND THEIR COMBINATIONS FOR THE APPLICATION OF CANCER DISEASES IN IMMUNOTHERAPY
EA202191120A EA202191120A3 (en) 2017-04-10 2018-04-10 PEPTIDES AND THEIR COMBINATIONS FOR USE IN CANCER IMMUNOTHERAPY

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201992417A EA201992417A1 (en) 2017-04-10 2018-04-10 PEPTIDES AND THEIR COMBINATIONS FOR THE APPLICATION OF CANCER DISEASES IN IMMUNOTHERAPY

Country Status (2)

Country Link
AR (1) AR111459A1 (en)
EA (2) EA201992417A1 (en)

Also Published As

Publication number Publication date
EA201992417A1 (en) 2020-02-20
AR111459A1 (en) 2019-07-17
EA202191120A2 (en) 2021-08-31

Similar Documents

Publication Publication Date Title
EA202191027A3 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF SEVERAL TYPES OF TUMORS
EA201992664A3 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF OVARIAN CANCER AND OTHER TYPES OF CANCER
EA201891670A1 (en) PEPTIDES, PEPTIDE COMBINATIONS AND CELL BASED MEDICATIONS FOR USING URINARY BLADDER AND OTHER CANCER IMMUNOTHERAPY
EA202091754A1 (en) PEPTIDES AND COMBINATIONS OF PEPTIDES OF NON-CANONIC ORIGIN FOR USE IN IMMUNOTHERAPY OF DIFFERENT TYPES OF CANCER
EA201891994A1 (en) Uterus Cancer Treatment
EA201992416A1 (en) PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN IMMUNOTHERAPY OF LEUKOSIS AND OTHER TYPES OF CANCER
EA201892159A1 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE USE OF AML AND OTHER CANCER IN IMMUNOTHERAPY
EA202190186A1 (en) PEPTIDES, COMBINATIONS OF PEPTIDES AND CELL-BASED MEDICINES FOR USE IN IMMUNOTHERAPY OF BLADDER CANCER AND OTHER TYPES OF CANCER
EA202191120A3 (en) PEPTIDES AND THEIR COMBINATIONS FOR USE IN CANCER IMMUNOTHERAPY
EA202091988A1 (en) PEPTIDES FOR USE IN IMMUNOTHERAPY OF CANCER
EA202190169A1 (en) IMMUNOTHERAPY OF CANCER DISEASES RESTRICTED ON B * 07 PEPTIDES AND COMBINATIONS OF PEPTIDES AND RELATED METHODS
EA202190555A1 (en) PEPTIDES RESTRICTED ON B * 44 FOR USE IN IMMUNOTHERAPY OF CANCER DISEASES AND RELATED METHODS
EA202190130A1 (en) PEPTIDES RESTRICTED ON A * 03 FOR USE IN IMMUNOTHERAPY OF CANCER AND RELATED METHODS
EA202190465A3 (en) NEW PEPTIDES AND PEPTIDE COMBINATIONS FOR USE IN NHL IMMUNOTHERAPY AND OTHER CANCER
EA202190572A1 (en) IMMUNOTHERAPY OF CANCER DISEASES RESTRICTED ON A * 01 PEPTIDES AND COMBINATIONS OF PEPTIDES AND RELATED METHODS
EA202191411A1 (en) IMMUNOTHERAPY OF CANCER DISEASES RESTRICTED ON B * 08 PEPTIDES AND COMBINATIONS OF PEPTIDES AND RELATED METHODS
EA202190357A3 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF SEVERAL TYPES OF CANCER
EA202190241A1 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF CLL AND OTHER TYPES OF CANCER
EA202190898A2 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF PANCREAS CANCER AND OTHER TYPES OF CANCER
EA202191013A2 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR OBTAINING FRAMEWORK FOR USE IN TREATMENT OF PANCREAS CANCER AND OTHER TYPES OF CANCER
EA202092542A2 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES AND FRAMEWORK FOR USE IN IMMUNOTHERAPY OF RENAL CELL CARCINOMA (RCC) AND OTHER TYPES OF CANCER
CR20200477A (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
EA202091864A3 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NON-SMALL CELL LUNG CANCER (NSCLC) AND OTHER TYPES OF CANCER